Ipamorelin

Approved source records

1. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

   Coutinho LFD, DE Oliveira Neves LF, Camilo RP. · 2026

   DOI: 10.23736/S0022-4707.26.17773-1PMID: 41880199

2. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

   Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · 2026

   DOI: 10.1177/03635465251357593PMID: 41476424

3. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

   Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ. · 2026

   DOI: 10.2106/JBJS.RVW.26.00027PMID: 42160466

4. Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

   Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr. · 2026

   DOI: 10.1177/03635465261464420PMID: 42578445

5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

   Mendias CL, Awan TM. · 2026

   DOI: 10.1007/s40279-026-02437-0PMID: 41966639

6. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

   Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. · 2026

   DOI: 10.3389/fendo.2026.1822475PMID: 42395176

7. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

   Renke G, Chinellato L. · 2026

   DOI: 10.3390/ijms27093890PMID: 42123471

8. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

   Rahman OF, Lee SJ, Seeds WA. · 2026

   DOI: 10.5435/JAAOSGlobal-D-25-00236PMID: 41490200

9. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

   Mavrych V, Shypilova I, Bolgova O. · 2026

   DOI: 10.3389/fragi.2026.1790247PMID: 42021992

10. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

    Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. · 2024

    DOI: 10.1016/j.physbeh.2024.114644PMID: 39043357

11. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.

    Gouda M, Ganesh CB. · 2024

    DOI: 10.1016/j.anireprosci.2024.107550PMID: 38996787

12. Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.

    N Mohammadi E, Louwies T, Pietra C, Northrup SR, Greenwood-Van Meerveld B. · 2020

    DOI: 10.2147/JEP.S249747PMID: 32801950

13. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. · 2020

    DOI: 10.21037/tau.2019.11.30PMID: 32257855

14. Analysis of new growth promoting black market products.

    Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M. · 2018

    DOI: 10.1016/j.ghir.2018.05.001PMID: 29864719

15. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

    Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. · 2014

    DOI: 10.1007/s00384-014-2030-8PMID: 25331030

16. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.

    Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. · 2012

    DOI: 10.2147/JEP.S35396PMID: 27186127

17. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.

    Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. · 2009

    DOI: 10.1124/jpet.108.149211PMID: 19289567

18. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.

    Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. · 2009

    DOI: 10.1016/j.ghir.2009.01.001PMID: 19231263

19. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

    Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. · 2002

    DOI: 10.14670/HH-17.707PMID: 12168778

20. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

    Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. · 2001

    DOI: 10.1006/bbrc.2000.4065PMID: 11162489

21. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

    Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. · 2001

    DOI: 10.1054/ghir.2001.0239PMID: 11735244

22. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

    Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. · 1999

    DOI: 10.1054/ghir.1999.9998PMID: 10373343

23. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

    Gobburu JV, Agersø H, Jusko WJ, Ynddal L. · 1999

    DOI: 10.1023/a:1018955126402PMID: 10496658

24. Ipamorelin, the first selective growth hormone secretagogue.

    Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. · 1998

    DOI: 10.1530/eje.0.1390552PMID: 9849822

25. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.

    Johansen PB, Hansen KT, Andersen JV, Johansen NL. · 1998

    DOI: 10.1080/004982598238976PMID: 9879640